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With you this morning…
Our partnership
www.epilepsy.org.uk www.parkinsons.org.uk
This presentation
We aim to share our experience of
§ Thinking through and developing an approach to 
topic refinement
§ Stakeholder engagement 
§ Developing web-based surveys and promoting 
participation
This presentation – how we did it 
 Task
 Approach
 Experience
 Learning
Our task
Our task
Seek stakeholder’s preferences for Cochrane systematic 
reviews to be produced as part of programme grant
§ topics relating to interventions and care
§ outcomes used or aspects of care for consideration 
in the reviews
We call this topic refinement
Our approach
Overview - priority setting approaches 
Technical
Use of existing data e.g. disease 
prevalence, economic burden, 
other measures
Scoring and use against matrix of 
criteria
Gap analysis or identified need 
e.g. Guidance and policy plans, 
commissioning health services 
Systematic review of existing 
priority sets 
Horizon and environmental 
scanning 
Cochrane criteria (e.g. 
downloads) or editorial decisions
Interpretive
Surveys to generate/ rank/
validate priorities (Delphi or other)
Using ‘free text’ data to inform 
above 
Creating/enriching scenarios to 
inform research topics and 
priorities 
Discussion among informed 
stakeholders to generate and or 
agree priorities; workshops, 
meetings.
Accessing patient narratives, help 
line data and proxy sources of 
perspectives
Approach 
Developed and piloted a 2 web-based surveys using 
SurveyMonkey (Advantage subscription):
§ Epilepsy
§ Parkinson's Disease
Worked closely with a small selection of epilepsy and Parkinson’s 
organisations to: 
§ Develop, test, improve the surveys
§ Market, engage and provide information to stakeholders
Developed a social media strategy and digital content:
§ /Priorities webpage on our Cochrane Groups’ sites
§ Text for tweets, handles (Twitter users) to target, retweet 
requests, hashtags
§ Visuals to support engagement (banners, slideshows)
Promotion (1)
Promotion (2)
§ Epilepsy Action and 
Parkinson’s UK facilitated 
access to their ‘research 
interested’ networks using 
targeted direct mail:
§ EA 8000 list members
§ PDUK 4500 list members
§ Our Cochrane groups emailed 
members (authors, consumer 
experts)
Promotion (3)
https://spark.adobe.com/video/LojNYUy3nLoIi
https://spark.adobe.com/video/Qhc6vEwBg6Eaa
Promotion (4)
The survey 
Preview topic development - Cochrane Epilepsy Group
The survey – some features/ functions
General approach
§ Mix of closed form, ranking and open form items on topics
§ Prioritisation using a sequence of selecting: 
§ top 10 à then top 5 à then ranking the top 5
Technical details*
§ Used the survey platform’s response ‘carry forward’ 
functionality
§ Topics initially presented to respondents in random order
§ Survey split into ‘pages’ to allow data capture without 
respondents reaching end page
§ Demographic questions at end and deliberately restricted 
in detail
!* WARNING – if you ask me about these, 
I will talk your ears off
Our experience
Reach
§ Open globally, but largely UK-based respondents
§ Over 1000 respondents:
§ 569 started the epilepsy survey
§ 470 started the Parkinson’s survey
§ Majority of respondents were people with the 
condition:
§ 59% epilepsy
§ 78% Parkinson’s
§ Few responses from professionals
Responses – top 5 topics (epilepsy, PD)
Perspectives shared – Epilepsy  
Preconception counselling for women – why is this important 
to you (127 responses)?
“I think pregnancy is a big worry for women with epilepsy so 
researching possible ways to reduce these anxieties and ensure 
women are supported is important.”
“This will be an issue for my daughter as she wants to have kids, 
but has not yet reached a satisfactory level of seizure control.”
Cannabinoids – why is this important to you (175 responses)?
“People are going nuts about CBD, presuming it will work for 
them and taking any form of cannabis that they can. It’s so 
dangerous and even the CBD alone - we don’t know the long-
term effects of it.”
“Lots of positive opinion and would like to see more evidence.” 
Perspectives shared – Parkinson’s Disease  
Nurse specialists – why is this important to you? (161 
responses)
“Evidence that nurse specialists are cost effective need to be 
persuasive so that there is a Parkinson's nurse for everyone with 
Parkinson's and that posts of Parkinson's nurses do not come 
under threat from financial cuts.”
“Good PD nurses are worth so much to PD people someone who 
understands and we can talk openly and honestly.”
Therapies for managing anxiety – why is this important to you 
(106 responses)
“…Socially limiting so patient opts out and enters a vicious 
downward cycle.”
“Anxiety has been the most distressing element on a day to day 
basis of my Parkinson's. Even being unable to walk properly is 
easier to deal with.”
How did we do? Cochrane KT guidance
Governance – team to 
develop the process
Shortlist by Cochrane groups, with 
external stakeholder reps. 
Refinement involved external 
experts & stakeholder reps.
Stakeholder engagement 
– external & internal to 
Cochrane
External: people with lived 
experience via in email & social 
media - reasonable numbers & 
diversity, some health 
professionals. Internal: via 
Cochrane group authors email, 
Consumer Facebook & KT group
Documentation &
dissemination
Process & findings to be written-up 
& disseminated (webinar soon). 
Priorities informed programme 
planning
Currency & timeframe Current for 2018-21
How did we do? REPRISE checklist 
1. Context and scope – UK based, interventional questions, SRs, 
epilepsy and Parkinson’s disease, medium term priorities. 
2. Governance and team – internal team, could have had more 
external members, some team members experienced in priority 
setting.
3. Inclusion of stakeholders – lived experience and specialist 
professionals (limited information), aim for 300 in each survey, 
no reimbursement for participation.
4. ID and collection of topics – previous prioritisation exercises, 
online survey, gathering topics in addition to set for 
prioritisation, known unknowns.
5. Prioritisation of topics – individual ‘forced’ online ranking, 
exclusions of other questions yet to be determined.
6. Outputs – Epilepsy ranked set, Parkinson’s Disease less clear 
priorities.
7. Evaluation and feedback – currently in this phase.
Our learning
Learning….(1)
§ Navigating from ‘gold’ to ‘good’
§ Staging approaches – topic shortlists, web-based 
approaches, workshops held in reserve
§ Focused engagement with a selection of 
stakeholders
§ Engaging target audience in testing and 
improvement of surveys
§ Integrating other topic research
§ Defining ‘systematic review’ – not easy!
Learning…(2)
§ Managing information shared by people with a 
condition
§ Choosing digital tools
?
This session
 Task
 Approach
 Experience
 Learning
Your views…
§ In what ways could we have done this better?
§ Was the approach good enough?
§ What would you want to know in a report/ 
publication?
§ How should we disseminate?
§ Is the lack of professional respondents an issue?
Next steps
§ Further analysis
§ Exploring free text for outcome preferences –
mapping with review protocols/ updates
§ Extension with expanded topic list for multinational 
stakeholders?
§ Cochrane Learning Live webinar – coming soon
§ Publication for dissemination and transparency –
summary on Cochrane Groups’ webpages at very 
least in addition to funder’s report
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